

Edgar Filing: OCEAN BIO CHEM INC - Form 8-K

OCEAN BIO CHEM INC  
Form 8-K  
July 15, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reportedly): December 24, 2008

OCEAN BIO-CHEM, INC.  
(Exact name of registrant as specified in charter)

Florida	2-11102	59-1564329
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4041 S.W. 47 Avenue, Fort Lauderdale, Florida 33314  
(Address of principal executive office Zip Code)

(954) 587-6280  
Registrant's telephone number, including area code:

Not Applicable  
(Former name or former address, if changes since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD

On December 23, 2008 The Company received correspondence from the NASDAQ Stock Market stating that they had recently extended its suspension of the Bid Price and Market Value of Publicly Held Shares requirements. Enforcement of these rules is currently scheduled to resume on April 20, 2009.

Prior to the resumption of these rules, NASDAQ indicated that they will contact the Company, stating the number of calendar days remaining in its compliance period and the specific date by which the Company needs to achieve

Edgar Filing: OCEAN BIO CHEM INC - Form 8-K

compliance.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

December 24, 2008

Ocean Bio-Chem, Inc.

/s/ Jeffrey S. Barocas  
Jeffrey S. Barocas  
Vice President - Finance and  
Chief Financial Officer